Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05143957




Registration number
NCT05143957
Ethics application status
Date submitted
20/11/2021
Date registered
3/12/2021
Date last updated
28/02/2024

Titles & IDs
Public title
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
Scientific title
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)
Secondary ID [1] 0 0
2021-003704-40
Secondary ID [2] 0 0
ISIS 702843-CS4
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Phlebotomy Dependent Polycythemia Vera 0 0
Condition category
Condition code
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - sapablursen

Experimental: Sapablursen Dose Level 1 - Sapablursen will be administered by SC injection every 4 weeks.

Experimental: Sapablursen Dose Level 2 - Sapablursen will be administered by SC injection every 4 weeks


Treatment: Drugs: sapablursen
Sapablursen will be administered by SC injection.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in the frequency of phlebotomy comparing Baseline with the last 20 weeks of the 37 week Treatment Period
Timepoint [1] 0 0
Week 17 to Week 37
Secondary outcome [1] 0 0
Proportion of patients achieving a reduction in the frequency of phlebotomy by = 30%, = 50%, = 75% and = 90% comparing Baseline with the last 20 weeks of the 37-week Treatment Period
Timepoint [1] 0 0
Week 17 to Week 37
Secondary outcome [2] 0 0
Change in the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF-TSS) From Baseline to Week 37
Timepoint [2] 0 0
Baseline up to Week 37

Eligibility
Key inclusion criteria
Inclusion Criteria

1. Meet modified World Health Organization (WHO) 2016 diagnostic criteria for
polycythemia vera (PV) at the time of clinical diagnosis

2. Participant must be phlebotomy dependent.

3. Participants do not need to be on cytoreductive therapy and do not need to have been
previously treated with cytoreductive therapy. If the patient was previously on
cytoreductive therapy it must have been discontinued at least 3 months prior to
Screening, with all associated AEs resolved. If the patient is currently on
cytoreductive therapy they must be on a stable dose of hydroxyurea, recombinant or
PEGylated interferon, or ruxolitinib for at least 3 months prior to Screening.
Minimum age
18 Years
Maximum age
90 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

1. Meets criteria for post-polycythemia vera myelofibrosis (PPV-MF) as defined by the
International Working Group- Myeloproliferative Neoplasms Research and Treatment
(IWG-MRT)

2. Moderate to severe splenic pain or spleen-related organ obstruction

3. Active or chronic bleeding within 1 month of Screening, significant concurrent/recent
coagulopathy, history of immune thrombocytopenic purpura (ITP)

4. Known primary or secondary immunodeficiency

5. Active infection with human immunodeficiency virus (HIV), hepatitis C, or hepatitis B.

6. Active infection requiring systemic antiviral or antimicrobial therapy or active novel
coronavirus disease (Covid-19) infection

7. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or
carcinoma in situ of the cervix or non-metastatic prostate cancer that has been
successfully treated

8. Surgery requiring general anesthesia within 1 month prior to Screening

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/12/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2025
Actual
Sample size
Target
60
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
St. George Hospital - Kogarah
Recruitment hospital [2] 0 0
Border Medical Oncology Research Unit - Albury
Recruitment hospital [3] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [4] 0 0
The Perth Blood Institute - West Perth
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
2640 - Albury
Recruitment postcode(s) [3] 0 0
3128 - Box Hill
Recruitment postcode(s) [4] 0 0
6005 - West Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Missouri
Country [6] 0 0
United States of America
State/province [6] 0 0
New Jersey
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
United States of America
State/province [11] 0 0
Wisconsin
Country [12] 0 0
Canada
State/province [12] 0 0
Quebec
Country [13] 0 0
Hungary
State/province [13] 0 0
Budapest
Country [14] 0 0
Hungary
State/province [14] 0 0
Debrecen
Country [15] 0 0
Poland
State/province [15] 0 0
Lublin
Country [16] 0 0
Poland
State/province [16] 0 0
Opole
Country [17] 0 0
Poland
State/province [17] 0 0
Slupsk
Country [18] 0 0
Poland
State/province [18] 0 0
Torun
Country [19] 0 0
United Kingdom
State/province [19] 0 0
England
Country [20] 0 0
United Kingdom
State/province [20] 0 0
London
Country [21] 0 0
United Kingdom
State/province [21] 0 0
West Bromwich

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Ionis Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the
frequency of phlebotomy and in improving quality of life assessments in participants with
polycythemia vera.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05143957
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Ionis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
(844) 673-0662
Fax 0 0
Email 0 0
IonisPDPVstudy@clinicaltrialmedia.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05143957